
FOR IMMEDIATE RELEASE

Eleison Pharmaceuticals Receives Approval from the CFDA to Begin Enrollment in China for its International Phase 3 Pancreatic Cancer Trial

Princeton, NJ, November 19, 2019 -- Eleison Pharmaceuticals LLC, ("Eleison"), a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced it has received approval from the China Food and Drug Administration (CFDA) to begin enrollment in China for its Phase 3 clinical trial of glufosfamide for pancreatic cancer. The Phase 3 trial is already ongoing with enrollment at ten sites in the United States.

Mr. Edwin Thomas, CEO of Eleison Pharmaceuticals commented, "Eleison is very pleased to receive approval from the CFDA to begin enrollment in China, which we believe will accelerate the timelines for completing our ongoing Phase 3 study of glufosfamide for pancreatic cancer – a disease associated with a very poor prognosis and few therapeutic options for patients."

About Glufosfamide

Glufosfamide is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects. It is currently being evaluated in a pivotal Phase 3 international randomized trial, for the second-line treatment of patients with pancreatic cancer. Although pancreatic cancer is among the rarer cancer types, it is the third leading cause of death by cancer in the United States. More than 53,000 Americans and 330,000 people worldwide are diagnosed with pancreatic cancer annually. There exist few therapeutic options to treat the disease and five year survival rates are typically less than 5%.

About Eleison Pharmaceuticals

Eleison's mission is to acquire and develop drug candidates with existing and significant safety and efficacy data; and ultimately to obtain regulatory approval and commercialize new therapeutics for patients with life-threatening cancers. The Company has two programs in late-stage development and is in discussions to acquire other promising oncology drug candidates. Eleison was founded in 2009 and is headquartered in Princeton, NJ. Additional information about Eleison can be found at our website www.eleison-pharma.com.

Forward Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

SOURCE/CONTACT: Eleison Pharmaceuticals LLC
Corporate Communications
100 Overlook Center, 2nd Floor
Princeton, NJ 08540
tel : 215-554-3530
email : info@eleison-pharma.com

FOR IMMEDIATE RELEASE
